You are here

Our science / Clinical Trials / Find a Trial / NCT00143416

Long Term Study With B2036-PEG

Back to Search Print Save as PDF Bookmark Trial

NCT00143416

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Kobe City, Hyogo Pref, 650-0017 Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acromegaly
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with acromegaly who have received at least one dose of B2036-PEG in the
preceding study (A6291009).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Switching to other therapeutic methods for acromegaly

NCT00143416
Pfizer
Completed
Long Term Study With B2036-PEG

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Acromegaly
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
NCT00151437
All Genders
18+
Years
Multiple Sites
Acromegaly
Pegvisomant And Sandostatin LAR Combination Study
NCT00068029
All Genders
18+
Years
Multiple Sites
Acromegaly
Long Term Use of Pegvisomant For A Regulatory Post Marketing Commitment Plan
NCT00658879
All Genders
Acromegaly
Long Term Study With B2036-PEG
NCT00143416
All Genders
20+
Years
Multiple Sites
Long Term Study With B2036-PEG
Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Acromegaly
Drug: Pegvisomant
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16
July 2007
Not Provided

Inclusion Criteria:

  • Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009).

Exclusion Criteria:

  • Switching to other therapeutic methods for acromegaly
Sexes Eligible for Study: All
20 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00143416
A6291011
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now